Abstract: A computer-implemented method for processing data associated with a simulation model, the simulation model being designed to simulate at least one aspect of a technical system. The method includes: ascertaining a first parameter group of parameters of the simulation model, whose sensitivity exceeds a predefinable sensitivity limiting value, ascertaining a substitute model for the simulation model based on the first parameter group, assessing a quality of the substitute model, a quality measure characterizing the quality of the substitute model being obtained.

Abstract: Heparinoid derivatives comprising a chelating agent which is covalently bonded to the heparinoid, and a paramagnetic metal cation from the series of transition metals Sc, Ti, V, Cr, Mn, Fe, Co, Ni, Cu, Mo, Ru or of the lanthanides, are suitable for producing medicaments both for therapy and for diagnostic purposes, for localizing the dose employed, and for monitoring the result of treatment of disorders such as thrombosis and osteoarthrosis.

Abstract: The present invention relates to the carboxyl-reduced derivatives of hyaluronic acid of formula (I): in which R or R1 represents H or SO3M, n is an integer of between 0 and 25 000, M is an alkali metal, isolated or as mixtures, to the diastereoisomers thereof, to the process for the preparation thereof, to the uses thereof as a medicinal product and to the pharmaceutical compositions containing them.

Abstract: The present invention relates to the carboxyl-reduced and chemoselectively O-sulfated derivatives of chondroitin sulfate of formula (I): in which R1, R2, R3 and R4 are H or SO3M, n is an integer of between 0 and 200, M is an alkali metal, isolated or as mixtures, to the diastereoisomers thereof, to the process for the preparation thereof, to the uses thereof as a medicinal product and to the pharmaceutical compositions containing them.

Abstract: The present invention relates to the carboxyl-reduced derivatives of dermatan sulfate of formula (I): in which R1, R2, R3 or R4 represents H or SO3M, n is an integer of between 0 and 150, M is an alkali metal, isolated or as mixtures, to the diastereoisomers thereof, to the process for the preparation thereof, to the uses thereof as a medicinal product and to the pharmaceutical compositions containing them.

Abstract: Heparinoid derivatives comprising a chelating agent which is covalently bonded to the heparinoid, and a paramagnetic metal cation from the series of transition metals Sc, Ti, V, Cr, Mn, Fe, Co, Ni, Cu, Mo, Ru or of the lanthanides, are suitable for producing medicaments both for therapy and for diagnostic purposes, for localizing the dose employed, and for monitoring the result of treatment of disorders such as thrombosis and osteoarthrosis.

Abstract: The present invention relates to a process for inactivating Carboxypeptidase Y (CPY) in a hirudin-containing culture broth produced by fermenting a transformed yeast. It has been found that inactive precursors of CPY are activated at a temperature 70.degree. C. and that the active peptidases will further degrade hirudin when the two proteins are present together in a composition. The present invention overcomes the CPY activation problem by heating a broth containing hirudin and CPY to a temperature of about 80.degree.-100.degree. C. in about one minute or less.

Abstract: The invention relates to novel synthetic isohirudins which have improved stability owing to exchange in the region of the Asp-Gly motif. This results, on the one hand, in an increase in the yield during workup and, on the other hand, in making possible pharmaceutical formulation as directly injectable solution ready for use.

Abstract: Novel synthetic isohirudins with improved stability The invention relates to novel synthetic isohirudins which have improved stability owing to exchange in the region of the Asp-Gly motif. This results, on the one hand, in an increase in the yield during workup and, on the other hand, in making possible pharmaceutical formulation as directly injectable solution ready for use.

Abstract: The invention relates to novel synthetic isohirudins which have improved stability owing to exchange in the region of the Asp-Gly motif. This results, on the one hand, in an increase in the yield during workup and, on the other hand, in making possible pharmaceutical formulation as directly injectable solution ready for use.

Abstract: Fusion proteins are obtained in high yields if a mixed oligonucleotide is constructed which codes for the ballast constituent of the fusion protein. The oligonucleotide mixture is introduced in a vector in such a manner that it is functionally linked to a regulatory region and to the structural gene for the desired protein. Appropriate host cells are transformed with the plasmid population obtained in this manner and the clones producing a high yield of coded fusion protein are selected.

Abstract: Partial sequences of human-.gamma.-interferon, comprising aminoacid sequences 5 to 127, 1 to 127 and 5 to 146, having biological activity. These partial sequences can be obtained by a genetic engineering process, for which purpose the appropriate DNA sequences are chemically synthesized. The DNA sequences are incorporated in hybrid plasmids, and the latter are introduced into host organisms and their expression is induced there. The biologically active polypeptides are suitable, as is human-.gamma.-interferon, for medicaments.

Abstract: A space diversity receiver with a combiner in which the useful signals of two space diversity receiver branches are connected together with a summing amplifier in the IF frequency band, and wherein an electronically controlled phase corrector P is mounted in one of the receiver branches and in which a phase monitoring circuit provides an output signal to control the phase corrector and is connected at the output of the electronic phase corrector between the two receiving branches. The space diversity receiver is constructed in the simplest possible manner with the lowest possible electrical interference and provides that the phase monitoring circuit consists of a phase discriminator D1 to which the signal from one reception branch is supplied through an automatically gain control amplifier RV2 without phase shift and the signal from the other receiving branch is supplied with an identical automatically gain controlled amplifier RV1 and through a 90-degree phase shifter.